[Improved clinical course of herpes zoster in immunosuppressed patients treated with fibroblast interferon].
In a randomized study with patients suffering from herpes zoster spread of eruptions was inhibited and segmental pain was reduced rapidly by continuous infusion of daily 0.5 X 10(6) IE fibroblast interferon/kg body weight for 3-5 days. Postherpetic neuralgia was observed more rarely and interferon healing of eruptions was accelerated by interferon compared to the controls.
D000328:Adult; D000368:Aged; D006562:Herpes Zoster / Q000503:physiopathology / Q000628:therapy*; D006801:Humans; D007165:Immunosuppression Therapy; D007263:Infusions, Parenteral; D007370:Interferon Type I / Q000008:administration & dosage / Q000627:therapeutic use*; D008875:Middle Aged; D059408:Pain Management
D007370:Interferon Type I
Günstigerer Verlauf des Herpes zoster bei immunsupprimierten Patienten unter Behandlung mit Fibroblasteninterferon.